Improving diabetes prevention with benefit based tailored treatment: risk based reanalysis of Diabetes Prevention Program
暂无分享,去创建一个
Jeremy B Sussman | David M Kent | Rodney A Hayward | J. Nelson | D. Kent | R. Hayward | J. Sussman | Jason P Nelson
[1] Nancy R Cook,et al. Statins: new American guidelines for prevention of cardiovascular disease , 2013, The Lancet.
[2] David M Kent,et al. Limitations of applying summary results of clinical trials to individual patients: the need for risk stratification. , 2007, JAMA.
[3] David M Kent,et al. Multivariable risk prediction can greatly enhance the statistical power of clinical trial subgroup analysis , 2006, BMC medical research methodology.
[4] M. Carnethon,et al. Comparative validity of 3 diabetes mellitus risk prediction scoring models in a multiethnic US cohort: the Multi-Ethnic Study of Atherosclerosis. , 2010, American journal of epidemiology.
[5] D. Kent,et al. Reporting clinical trial results to inform providers, payers, and consumers. , 2005, Health affairs.
[6] G. Collins,et al. Developing risk prediction models for type 2 diabetes: a systematic review of methodology and reporting , 2011, BMC medicine.
[7] S. Inzucchi,et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach. Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012;35:1364–1379 , 2013, Diabetes Care.
[8] Jeremy B. Sussman,et al. Individual and Population Benefits of Daily Aspirin Therapy: A Proposal for Personalizing National Guidelines , 2011, Circulation. Cardiovascular quality and outcomes.
[9] Ewout W Steyerberg,et al. Estimating treatment effects for individual patients based on the results of randomised clinical trials , 2011, BMJ : British Medical Journal.
[10] Ewout W Steyerberg,et al. Validation and updating of predictive logistic regression models: a study on sample size and shrinkage , 2004, Statistics in medicine.
[11] Edward H. Kennedy,et al. Improved Cardiovascular Risk Prediction Using Nonparametric Regression and Electronic Health Record Data , 2013, Medical care.
[12] Ralph B D'Agostino,et al. Prediction of incident diabetes mellitus in middle-aged adults: the Framingham Offspring Study. , 2007, Archives of internal medicine.
[14] Jim Bellows,et al. Use of IndiGO individualized clinical guidelines in primary care , 2013, J. Am. Medical Informatics Assoc..
[15] Melvin Prince,et al. The Diabetes Prevention Program. Design and methods for a clinical trial in the prevention of type 2 diabetes. , 1999, Diabetes care.
[16] D. Matthews,et al. Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach , 2012, Diabetes Care.
[17] S. Fowler,et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. , 2002 .
[18] Andrew J Vickers,et al. Method for evaluating prediction models that apply the results of randomized trials to individual patients , 2007, Trials.
[19] E. Elkin,et al. Decision Curve Analysis: A Novel Method for Evaluating Prediction Models , 2006, Medical decision making : an international journal of the Society for Medical Decision Making.
[20] Rodney A Hayward,et al. Moneyball, gambling, and the new cholesterol guidelines. , 2014, Circulation. Cardiovascular quality and outcomes.
[21] P. Rothwell. Subgroup analysis in randomised controlled trials: importance, indications, and interpretation , 2005, The Lancet.
[22] R Core Team,et al. R: A language and environment for statistical computing. , 2014 .
[23] Ping Zhang,et al. The 10-Year Cost-Effectiveness of Lifestyle Intervention or Metformin for Diabetes Prevention , 2012, Diabetes Care.
[24] J. Lau,et al. The impact of high-risk patients on the results of clinical trials. , 1997, Journal of clinical epidemiology.
[25] David M Kent,et al. Assessing and reporting heterogeneity in treatment effects in clinical trials: a proposal , 2010, Trials.
[26] David M. Kent,et al. Using Internally Developed Risk Models to Assess Heterogeneity in Treatment Effects in Clinical Trials , 2014, Circulation. Cardiovascular quality and outcomes.
[27] J. Concato,et al. Importance of events per independent variable in proportional hazards regression analysis. II. Accuracy and precision of regression estimates. , 1995, Journal of clinical epidemiology.
[28] M. Molitch. Effects of withdrawal from metformin on the development of diabetes in the diabetes prevention program. , 2003, Diabetes care.
[29] R. Hayward,et al. Prevalence, Diagnosis, and Treatment of Impaired Fasting Glucose and Impaired Glucose Tolerance in Nondiabetic U.S. Adults , 2010, Diabetes Care.